Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with treatment-resistant depression (TRD) are those with major depressive disorder that has not responded adequately to treatment. The causes of depression are not fully understood, although there is evidence to suggest that depression is a complex interaction among biological, genetic, psychosocial and environmental factors. Strategies available for the treatment of patients with TRD include pharmacological, non-pharmacological, and psychological and psychosocial interventions. Pharmacological treatment options include switching to a different antidepressant, the addition of another antidepressant of a different class, or use of an augmenting agent, such as anticonvulsants, lithium or atypical antipsychotics (AAPs). However, there is limited evidence available on the effectiveness of these strategies in the treatment of TRD. OBJECTIVES: To estimate the clinical effectiveness and cost-effectiveness of augmentation of selective serotonin reuptake inhibitor (SSRI) antidepressant therapy with either lithium or an AAP drug in the management of people with treatment-resistant unipolar depression, defined as failure to respond to two or more antidepressant drugs in their current episode of depression. DATA SOURCES: Databases searched were Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, MEDLINE, PsycINFO and NHS Economic Evaluation Database (NHS EED). All databases were searched from inception to August 2011. Additional data were obtained from manufacturers. REVIEW METHODS: Systematic reviews of studies evaluating clinical effectiveness, economic analyses and quality of life (QoL) were executed. Quality assessment according to predefined criteria was undertaken independently by two reviewers. Pairwise meta-analyses and mixed-treatment comparisons (MTCs) using both fixed- and random-effects models were undertaken based on intention-to-treat analyses. A probabilistic de novo mathematical model was developed to synthesise the available data on costs and clinical outcomes from the UK NHS perspective over a 1-year time horizon (8 weeks of acute treatment captured by a decision tree and 10 months of maintenance treatment captured by a Markov model). RESULTS: Twelve randomised controlled trials (RCTs) were identified in the review of clinical effectiveness literature; 10 considered SSRI + AAP compared with SSRI + placebo/no treatment, one considered SSRI + AAP compared with SSRI + lithium and one considered SSRI + lithium compared with SSRI + placebo. The RCTs included in the primary analyses used fluoxetine as the background SSRI and olanzapine as the AAP. Results of the MTC showed a non-significant trend in favour of lithium augmentation for response [lithium a priori odds ratio (OR) 1.29; 95% credible interval (CrI) 0.11 to 5.32; lithium post hoc OR 4.15; 95% CrI 0.25 to 20.34 (the trial informing the comparison with lithium reported response using two different definitions)], mean change in Montgomery-Åsberg Depression Rating Scale score from baseline (mean difference - 1.47, 95% CrI - 9.10 to 6.41) and all-cause withdrawals (OR 0.74, 95% CrI 0.10 to 2.66). Four economic evaluations (none directly addressing the review question) and 17 studies that reported on QoL were identified and summarised in narrative reviews. The results of the de novo modelling indicate that augmentation of SSRI with lithium dominates augmentation of an SSRI with AAP (i.e. it resulted in cost savings of £905 per person per year and generated more health benefits, estimated to be 0.03 quality-adjusted life-years). However, sensitivity analyses showed that the model was highly sensitive to changes in acute treatment efficacy (response and remission) or discontinuation. The model was not sensitive to changes in other parameters. LIMITATIONS: In patients with TRD, there is a lack of direct evidence comparing the clinical effectiveness of augmenting an SSRI with an AAP compared with augmenting with lithium. RCTs were identified which facilitated comparison of adding AAP with adding lithium via a MTC. However, variations in the definitions of response implemented in the RCTs, together with differences in patient baseline characteristics across RCTs, introduce bias into the analysis. The direction and extent of the bias is uncertain. CONCLUSIONS: Augmentation of SSRIs with lithium or AAP is likely to be beneficial in people with TRD. Clinical evaluation based on the limited evidence identified in this research indicates no statistically significant difference between the two augmentation strategies. Cost-effectiveness analyses suggest that augmentation with lithium is less expensive and more effective than augmentation with AAP. However, the uncertainty in the clinical estimates of discontinuation and treatment response is reflected in the model results. A RCT comparing the two augmentation strategies, reporting relevant outcomes, including QoL, is needed. STUDY REGISTRATION: PROSPERO CRD42011001464.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Funnel plots for detecting bias in meta-analysis
Sterne, J. A. C., & Egger, M. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00377-8 · Cited by 3,779
Simultaneous comparison of multiple treatments: Combining direct and indirect evidence.
Caldwell, D. M., Ades, A. E., & Higgins, J. P. T. (2005) · BMJ · doi:10.1136/bmj.331.7521.897 · Cited by 1,600
Affective disorders and suicide risk: a reexamination
Bostwick, J. M., & Pankratz, V. S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.12.1925 · Cited by 878
Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707
Harmer, C. J., Goodwin, G. M., & Cowen, P. J. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.051193 · Cited by 542
Marcus, R. N., McQuade, R. D., Carson, W. H., Hennicken, D., Fava, M., Simon, J. S., Trivedi, M. H., Thase, M. E., & Berman, R. M. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31816774f9 · Cited by 518
Effect of Acute Antidepressant Administration on Negative Affective Bias in Depressed Patients
Harmer, C. J., O’Sullivan, U., Favaron, E., Massey-Chase, R., Ayres, R., Reinecke, A., Goodwin, G. M., & Cowen, P. J. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09020149 · Cited by 485
McCabe, C., Mishor, Z., Cowen, P. J., & Harmer, C. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.11.001 · Cited by 365
Berman, R. M., Fava, M., Thase, M. E., Trivedi, M. H., Swanink, R., McQuade, R. D., Carson, W. H., Adson, D., Taylor, L., Hazel, J., et al. (2009) · CNS Spectrums · doi:10.1017/s1092852900020216 · Cited by 260
Crossley, N. A., & Bauer, M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0617 · Cited by 246
Dunner, D. L., Rush, A. J., Russell, J. M., Burke, M., Woodard, S., Wingard, P., & Allen, J. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0501 · Cited by 234
Zimmerman, M., Posternak, M. A., & Chelminski, I. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2004.03.007 · Cited by 229
Thase, M. E., Corya, S. A., Osuntokun, O., Case, M., Henley, D. B., Sanger, T. M., Watson, S. B., & Dubé, S. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0207 · Cited by 228
Bauer, M., Pretorius, H. W., Constant, E. L., Earley, W. R., Szamosi, J., & Brecher, M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04629 · Cited by 210
A Systematic Review of Treatments for Refractory Depression in Older People
Cooper, C., Katona, C., Lyketsos, K., Blazer, D., Brodaty, H., Rabins, P., de Mendonça Lima, C. A., & Livingston, G. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10081165 · Cited by 176
Corya, S. A., Williamson, D., Sanger, T. M., Briggs, S. D., Case, M., & Tollefson, G. (2006) · Depression and Anxiety · doi:10.1002/da.20130 · Cited by 170
Corya, S. A. (2005) · doi:10.4088/jcp.v66n1012 · Cited by 162
Sapin (2004) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-2-20 · Cited by 161
McIntyre, A., Gendron, A., & McIntyre, A. (2007) · Depression and Anxiety · doi:10.1002/da.20275 · Cited by 145
Risperidone for Treatment-Refractory Major Depressive Disorder: A Randomized Trial
Mahmoud, R. A., Pandina, G. J., Turkoz, I., Kosik-Gonzalez, C., Canuso, C. M., Kujawa, M. J., & Gharabawi-Garibaldi, G. M. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-9-200711060-00003 · Cited by 140
Economic implications of treatment-resistant depression among employees
Greenberg, P., Corey-Lisle, P. K., Birnbaum, H., Marynchenko, M., & Claxton, A. (2004) · PharmacoEconomics · doi:10.2165/00019053-200422060-00003 · Cited by 113
Keitner, G. I., Garlow, S. J., Ryan, C. E., Ninan, P. T., Solomon, D. A., Nemeroff, C. B., & Keller, M. B. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.05.003 · Cited by 108
Simpson, K. N., Welch, M. J., Kozel, F. A., Demitrack, M. A., & Nahas, Z. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0013-x · Cited by 90
Changes in daily life experience associated with clinical improvement in depression
Barge-Schaapveld, D. (1995) · Journal of Affective Disorders · doi:10.1016/0165-0327(95)00012-c · Cited by 84
A Systematic Review of Augmentation Strategies for Patients with Major Depressive Disorder
Fleurence, R., Williamson, R., Jing, Y., Kim, E., Tran, Q.-V., Pikalov, A., & Thase, M. E. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4089 · Cited by 65
Montgomery-Asberg Depression Rating Scale
Montgomery, S. A., & Asberg, M. (2012) · PsycTESTS Dataset · doi:10.1037/t04111-000 · Cited by 25
Long-Term Impact of Residual Symptoms in Treatment-Resistant Depression
Fekadu, A., Wooderson, S. C., Rane, L. J., Markopoulou, K., Poon, L., & Cleare, A. J. (2011) · The Canadian Journal of Psychiatry · doi:10.1177/070674371105600906 · Cited by 23
Cited by
Defining treatment‐resistant depression
Gaynes, B. N., Lux, L., Gartlehner, G., Asher, G., Forman‐Hoffman, V., Green, J., Boland, E., Weber, R. P., Randolph, C., Bann, C., et al. (2020) · Depression and Anxiety · doi:10.1002/da.22968 · Cited by 447
Economic impact of treatment-resistant depression: A retrospective observational study
Pérez-Sola, V., Roca, M., Alonso, J., Gabilondo, A., Hernando, T., Sicras-Mainar, A., Sicras-Navarro, A., Herrera, B., & Vieta, E. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.08.036 · Cited by 55
Barton, S., Karner, C., Salih, F., Baldwin, D. S., & Edwards, S. J. (2014) · Health Technology Assessment · doi:10.3310/hta18500 · Cited by 36
“When used as an adjunctive treatment for treatment-resistant anxiety or depression, antipsychotics have predominantly been added to a SSRI (typically fluoxetine).(63,78) A systematic review of augmentation of pharmacotherapy in treatment-resistant anxiety disorders found that augmentation of ongoing therapy with an an…”
Self-citationLähteenvuo, M., Taipale, H., Tanskanen, A., Rannanpää, S., & Tiihonen, J. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.04.010 · Cited by 20
Metadata
- Authors
- Edwards, S., Hamilton, V, Nherera, L., & Trevor, N.
- Venue
- Health Technology Assessment
- Published
- 2013-11
- Volume
- 17
- Issue
- 54
- Pages
- 1-190
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W1968906980
- Cited by
- 71
- References
- 28
- FWCI
- 1.14
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.